<DOC>
	<DOCNO>NCT01897714</DOCNO>
	<brief_summary>The study explore escalate dos melflufen combination dexamethasone small group patient find maximum tolerate dose melflufen . That dose use determine efficacy safety profile melflufen combination dexamethasone large group patient .</brief_summary>
	<brief_title>Safety Efficacy Melflufen Dexamethasone Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Male female , age 18 year old 2 . Patient diagnosis multiple myeloma document relapsed and/or relapsedrefractory disease 3 . Patient measurable disease define follow : 1 . Serum monoclonal protein ≥ 0.5 g/dL protein electrophoresis 2 . ≥200 mg monoclonal protein urine 24hour electrophoresis 3 . Serum immunoglobulin free light chain ≥10 mg/dL AND abnormal serum immunoglobulin kappa lambda free light chain ratio 4 . If monoclonal protein detect , ≥ 30 % monoclonal bone marrow plasma cell 4 . Patient least 2 prior line therapy include lenalidomide bortezomib demonstrate disease progression within 60 day completion last therapy 5 . Life expectancy ≥6 month 6 . Patient ECOG performance status ≤ 2 ( Patients low performance status base solely bone pain secondary multiple myeloma eligible ) 7 . Females childbearing potential must negative serum urine pregnancy test prior patient registration 8 . Female patient child bear potential nonvasectomized male patient agree practice appropriate method birth control 9 . Ability understand purpose risk study provide sign date informed consent authorization use protect health information 10 . The patient , accepts , acceptable infusion device infusion melflufen 11 . 12 lead ECG QtcF interval ≤ 470 msec 12 . The following laboratory result must meet within 21 day patient registration : Absolute neutrophil count ≥ 1,000 cells/dL ( 1.0 x 109/L ) Platelet count ≥ 75,000 cells/dL ( 75 x 109/L ) Hemoglobin ≥ 8.0 g/dL Total Bilirubin ≤ 1.5 x upper limit normal Renal function : Estimated creatinine clearance ≥ 45 ml/min serum creatinine ≤ 2.5 mg/dL AST ( SGOT ) ALT ( SGPT ) ≤ 3.0 x ULN 1 . Patient evidence mucosal internal bleeding and/or platelet transfusion refractory 2 . Any medical condition , Investigator 's opinion , would impose excessive risk patient would adversely affect his/her participation study 3 . Known active infection require parenteral oral antiinfective treatment 4 . Other malignancy within past 3 year exception adequately treat basal cell carcinoma , squamous cell skin cancer , carcinoma insitu cervix 5 . Other ongoing antimyeloma therapy . Patients may receive concomitant therapy bisphosphonates low dose corticosteroid symptom management comorbid condition . Doses corticosteroid stable least 7 day prior patient registration . 6 . Pregnant breastfeeding female 7 . Serious psychiatric illness , active alcoholism , drug addiction may hinder confuse followup evaluation 8 . Known HIV hepatitis B C viral infection 9 . Patient concurrent symptomatic amyloidosis plasma cell leukemia 10 . POEMS syndrome 11 . Previous cytotoxic therapy , include cytotoxic investigational agent , multiple myeloma within 3 week ( 6 week nitrosoureas ) prior start study treatment . Biologic , novel therapy ( include investigational agent class ) corticosteroid within 2 week prior patient registration . Patient side effect previous therapy &gt; grade 1 previous baseline . 12 . Prior peripheral stem cell transplant within 12 week patient registration 13 . Radiotherapy within 21 day prior Cycle 1 Day 1 . However , radiation portal cover ≤ 5 % bone marrow reserve , patient may enrol irrespective end date radiotherapy 14 . Known intolerance steroid therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>